Clinical Challenges in Lipid Disorders 1st Edition by Peter P Toth, Domenic A ISBN 1846920299 9781846920295

Clinical Challenges in Lipid Disorders 1st Edition by Peter P Toth, Domenic A – Ebook PDF Instant Download/Delivery: 1846920299, 9781846920295
Full download Clinical Challenges in Lipid Disorders 1st Edition after payment

Product details:

ISBN 10: 1846920299 
ISBN 13: 9781846920295
Author: Peter P Toth, Domenic A

Clinical Challenges in Lipid Disorders 1st Table of contents:

• Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview

  • Early History of Cardiovascular Epidemiology
  • Lipid Risk Factors are Central to Efforts at CHD Prevention
  • LDL-C and CHD Risk
  • LDL-C Lowering and CHD Risk Reduction
  • Other Atherogenic Lipoproteins: Atherogenic Remnants
  • HDL-C and CHD Risk
  • Trends in Lipids and Lipid Management in the USA
  • The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II Survey
  • Controversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?

• Vascular Biology and Atherogenesis

  • Introduction
  • Arterial Structure
  • Endothelial Cell Function and Dysfunction
  • The Role of Monocytes and Lymphocytes
  • Atheromatous Plaques

• Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults

  • Matching Aggressiveness of Treatment to Absolute Risk
  • Screening for Dyslipidemias
  • Risk Stratification
  • Steps in the Risk Stratification Process – Major Risk Categories
  • Tips for Calculating the Framingham Risk Score
  • Subcategories for Consideration of More Aggressive Optional Treatment Goals
  • Very High Risk Patients, Optional LDL-C Goal <70 mg dl⁻¹
  • Moderately High Risk Patients, OPTIONAL LDL-C Goal <100 mg dl⁻¹
  • Treatment Goals for Patients with Elevated Triglycerides
  • Triglycerides and HDL-C as Targets for Therapy
  • Controversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?

• Therapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome

  • Nature and Nurture in the Development of CHD Risk Factors
  • Lifestyle Factors as Determinants of CHD Risk in Populations
  • Within Country Variations in Lifestyle and CHD Risk
  • The Metabolic Syndrome
  • Therapeutic Lifestyle Changes
  • The TLC Diet
  • Dietary Adjuncts: Viscous Fibers and Plant Sterol/Stanol Products
  • Physical Activity and Weight Reduction
  • Smoking Cessation
  • Importance of Allied Health Professionals

• Management of Elevated Low-Density Lipoprotein Cholesterol

  • Relationship between LDL-C and Risk for Cardiovascular Events
  • Clinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk
  • Genetic Disorders Associated with Elevated LDL-C
  • Atherogenic Impact of LDL-C
  • Management of Elevated LDL-C
  • Summary
  • Controversy: How Low Should We Go?
  • Controversy: Risks and Benefits of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy
  • Controversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on “How Low You Go” or also on “How You Get There”?

• Management of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol

  • Clinical Factors Associated with Elevated TG and Non-HDL-C Levels
  • Disorders of TG-Rich Lipoprotein Clearance
  • Insulin Resistance and Hypertriglyceridemia
  • Excessive Production of VLDL: The Primary Lipid Abnormality in the Insulin-Resistant State
  • Reasons for Elevated Free Fatty Acid Levels in Insulin-Resistant States

  • Body Fat Distribution and Insulin Resistance
  • Insulin Resistance in the Nonobese Patient
  • Hypertriglyceridemia and the Development of Atherogenic Dyslipidemia
  • Lifestyle Management for the Metabolic Syndrome and Atherogenic Dyslipidemia
  • Drug Therapies
  • Intensification of Efforts to Lower LDL-C as a Means of Achieving the Non-HDL-C Goal
  • Targeting Triglyceride-Rich Lipoprotein Reduction as a Means of Achieving Non-HDL-C Goal

  • Fibrates
  • Niacin
  • Omega-3 Fatty Acids
  • Management of Diabetic Dyslipidemia
  • Controversy: Do we Need a Triglyceride Treatment Target to Insure a Predominance of Larger, More Buoyant LDL Particles?

• Additional Chapters/Case Studies: (The book is known to contain more than twenty cases presenting complex choices. These would be organized into further chapters or specific case presentations).

  • Topics would likely include:
    • Management of specific lipid disorders (e.g., Familial Hypercholesterolemia, Mixed Dyslipidemia)
    • Lipid management in special populations (e.g., in patients with diabetes, chronic kidney disease, or in children/adolescents)
    • Addressing statin intolerance and side effects
    • Emerging therapies and future directions in lipid management

People also search for Clinical Challenges in Lipid Disorders 1st:

clinical challenges in lipid disorders
    
lipid disorders in adults
    
lipid disorders clinic
    
lipid disorders in adults (cholesterol dyslipidemia) screening
    
clinical lipidology

Tags: Peter P Toth, Domenic A, Clinical, Challenges